NovoCure shareholders elect 11 directors, approve ESPP; President awarded 179,426 RSUs

NovoCure Ltd

Shareholders elected all 11 director nominees with >81M votes each; 92.98M shares represented (~83.4%).
Say-on-pay approved: 80.6M for, 2.0M against, ~10M broker non-votes.
2025 Employee Share Purchase Plan approved: 82.0M for, 0.68M against; reserves 6,507,843 shares (less prior plan shares).
Francis Leonard appointed President, Novocure and awarded 179,426 RSUs vesting in two equal annual installments.

item 5.02 item 5.07 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Francis Leonard

President, Novocure

NVCR · NovoCure Ltd

Effective: 2025-06-04
Filed: June 6, 2025, 7:59 PM ET

In connection with his appointment of the title "President, Novocure" on June 4, 2025 (the "Award Date"), Francis Leonard, formerly the Company's Executive Vice President, President Novocure Oncology, was awarded 179,426 Restricted Share Units

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Francis Leonard was appointed as President, Novocure at NovoCure Ltd.

Action: appointed
Role: President, Novocure

Exact text from the filing

In connection with his appointment of the title "President, Novocure" on June 4, 2025 (the "Award Date"), Francis Leonard, formerly the Company's Executive Vice President, President Novocure Oncology, was awarded 179,426 Restricted Share Units

View on SEC.gov

NovoCure Ltd filing history →

Source: SEC EDGAR

accession 0001645113-25-000011

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.